Published on
November 24, 2020
- 06:00 GMT
ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment ...
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT) 200 mg once …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
